Tumour-induced immunity to H-Y-disparate skin grafts without concomitant priming of CTL.
A tumour, ET-5, arising as a subcutaneous mass in a C57BL/6 male mouse after treatment with a mutagen, has been found to elicit immunity to H-Y antigen in B6 female mice that have rejected the tumour. Anti-H-Y immunity is demonstrable in vivo by accelerated rejection of male skin grafts, and by the ability of spleen cells from ET-5-primed female mice to transfer immunity against H-Y antigen to immunodeficient hosts given indicator male skin grafts. However, spleen cells from ET-5-immune female mice fail to generate CTL specific for H-Y antigen when co-cultured with male stimulator cells in vitro. This finding implies that the generation of H-Y-specific immunity in vivo can occur in the absence of priming of CTL, and thus calls into question the necessity for CTL participation in H-Y-disparate tumour graft rejection.
Johnson
L L
LL
Trudeau Institute Inc., Saranac Lake, New York 12983.
Hines
D L
DL
D000818:Animals; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D005260:Female; D006084:Graft Rejection / Q000276:immunology; D006182:H-Y Antigen / Q000276:immunology*; D015395:Histocompatibility Antigens Class I / Q000032:analysis; D007109:Immunity / Q000276:immunology; D007116:Immunization, Passive; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008815:Mice, Inbred Strains; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000276:immunology*; D016038:Skin Transplantation / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
D006182:H-Y Antigen; D015395:Histocompatibility Antigens Class I